5 Most Undervalued Biotech Stocks To Buy According To Hedge Funds
In this article, we will take a look at the 5 most undervalued biotech stocks to buy according to hedge funds.
Iteos Therapeutics Inc. (ITOS)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 3,649,057 | $21,784,870 | +75% | 0.36% |
| 2. | Biotechnology Value Fund / BVF Inc Mark Lampert | 3,075,000 | $18,357,750 | +33% | 0.75% |
| 3. | Tang Capital Management Kevin C. Tang | 2,689,200 | $16,054,524 | +1113% | 0.89% |
| 4. | 683 Capital Partners Ari Zweiman | 1,750,000 | $10,447,500 | +91% | 0.72% |
| 5. | BioImpact Capital Mpm Capital | 1,745,943 | $10,423,280 | 1.79% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.00 | 3,300,000 | Large Shareholder | 10,688,978 | 2025-05-15 | Filing | |
| $7.41 | 1,658,978 | Large Shareholder | 7,388,978 | 2025-05-14 | Filing | |
| $7.73 | 5,000 | 65,429 | 2024-11-19 | Filing | ||
| $8.37 | 5,000 | Officer | 19,429 | 2023-10-12 | Filing | |
| $32.85 | 20,000 | Director | 3,192,058 | 2022-03-23 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $8.06 | 1,031,931 | 3,452,797 | 2025-05-13 | Filing | ||
| $8.06 | 630,191 | 2,108,594 | 2025-05-13 | Filing | ||
| $8.06 | 630,191 | 2,108,594 | 2025-05-13 | Filing | ||
| $16.87 | 219,638 | 1,804,058 | 2023-08-23 | Filing | ||
| $15.63 | 95,516 | 2,023,696 | 2023-08-23 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,509,247 | $26,920,204 | 0% | |
| 2. | 2,738,785 | $16,350,546 | 23.55% | |
| 3. | 1,982,663 | $11,836,499 | 0% | |
| 4. | 1,726,458 | $10,306,955 | 0% | |
| 5. | 1,181,254 | $7,052,881 | 0% |
News See All
12 Most Undervalued Pharma Stocks To Buy According To Hedge Funds
In this article, we discuss 12 most undervalued pharma stocks to buy according to hedge funds.
Hedge Fund and Insider Trading News: Christopher Hohn, Gramercy Funds Management, Citadel LLC, Starboard Value LP, WizardQuant, Momentum Global Investment Management, iTeos Therapeutics Inc (ITOS), and More
(Yicai Global) March 25 -- If the United States were to decouple from China, it would slow innovation, Ken Griffin, founder and chief executive of US financial firm Citadel LLC, said in a recent interview...
Is ITOS A Good Stock To Buy Now?
While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, virus news and stimulus talks, many smart money investors are starting to get cautious...
Billionaire Hedge Funds
